Literature DB >> 21984361

Transcoronary ethanol ablation for recurrent ventricular tachycardia after failed catheter ablation: an update.

Michifumi Tokuda1, Piotr Sobieszczyk, Andrew C Eisenhauer, Pipin Kojodjojo, Keiichi Inada, Bruce A Koplan, Gregory F Michaud, Roy M John, Laurence M Epstein, Frédéric Sacher, William G Stevenson, Usha B Tedrow.   

Abstract

BACKGROUND: Despite substantial progress, radiofrequency catheter ablation (RFCA) fails in some patients. After encouraging results with transcoronary ethanol ablation (TCEA), we began offering TCEA routinely when endocardial and epicardial RFCA failed or a deep intramural substrate was likely. METHODS AND
RESULTS: Among 274 consecutive patients who underwent 408 ventricular tachycardia (VT) ablation procedures, 27 patients (21 men; age, 63 ± 13 years; left ventricular ejection fraction, 30 ± 11%; ischemic cardiomyopathy, 14) had 29 TCEA procedures attempted. In 5 patients, TCEA was abandoned because of unfavorable anatomy. In 22 patients, a mean of 1.3 ± 0.6 arteries (range, 1-3 arteries) were targeted for TCEA. After ablation, the targeted VT was no longer inducible in 18 of 22 (82%) patients. Complete heart block occurred in 5 patients, and 3 patients with advanced heart failure died within 30 days of the procedure. After the last TCEA procedure, a VT recurred in 64% of patients, and overall, 32% of patients died. Of 11 patients with prior VT storm, 9 were free of VT storm. At repeat study in 8 patients who had a recurrence, 7 had a new QRS morphology of VT originating from the same general substrate region as the prior VT.
CONCLUSIONS: In patients with difficult-to-control VT in whom RFCA fails, TCEA prevents all VT recurrences in 36% and improves arrhythmia control in an additional 27%. Inadequate target vessels, collaterals, and recurrence of modified VTs limit efficacy, but TCEA continues to play an important role for difficult VTs in these high-risk patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21984361     DOI: 10.1161/CIRCEP.111.966283

Source DB:  PubMed          Journal:  Circ Arrhythm Electrophysiol        ISSN: 1941-3084


  33 in total

1.  2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias.

Authors:  Edmond M Cronin; Frank M Bogun; Philippe Maury; Petr Peichl; Minglong Chen; Narayanan Namboodiri; Luis Aguinaga; Luiz Roberto Leite; Sana M Al-Khatib; Elad Anter; Antonio Berruezo; David J Callans; Mina K Chung; Phillip Cuculich; Andre d'Avila; Barbara J Deal; Paolo Della Bella; Thomas Deneke; Timm-Michael Dickfeld; Claudio Hadid; Haris M Haqqani; G Neal Kay; Rakesh Latchamsetty; Francis Marchlinski; John M Miller; Akihiko Nogami; Akash R Patel; Rajeev Kumar Pathak; Luis C Saenz Morales; Pasquale Santangeli; John L Sapp; Andrea Sarkozy; Kyoko Soejima; William G Stevenson; Usha B Tedrow; Wendy S Tzou; Niraj Varma; Katja Zeppenfeld
Journal:  J Interv Card Electrophysiol       Date:  2020-10       Impact factor: 1.900

Review 2.  Ethanol for the treatment of cardiac arrhythmias.

Authors:  Paul Schurmann; Jorge Peñalver; Miguel Valderrábano
Journal:  Curr Opin Cardiol       Date:  2015-07       Impact factor: 2.161

Review 3.  Review on sudden death risk reduction after septal reduction therapies in hypertrophic obstructive cardiomyopathy.

Authors:  Angelos G Rigopoulos; Muhammad Ali; Elena Abate; Marios Matiakis; Hannes Melnyk; Sophie Mavrogeni; Dionyssios Leftheriotis; Boris Bigalke; Michel Noutsias
Journal:  Heart Fail Rev       Date:  2019-05       Impact factor: 4.214

4.  Retrograde Coronary Venous Ethanol Infusion for Ablation of Refractory Ventricular Tachycardia.

Authors:  Bahij Kreidieh; Moisés Rodríguez-Mañero; Paul Schurmann; Sergio Hugo Ibarra-Cortez; Amish S Dave; Miguel Valderrábano
Journal:  Circ Arrhythm Electrophysiol       Date:  2016-07

5.  Coronary venous ethanol infusion for the treatment of refractory ventricular tachycardia.

Authors:  Alex Baher; Dipan J Shah; Miguel Valderrabano
Journal:  Heart Rhythm       Date:  2012-06-06       Impact factor: 6.343

6.  2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias.

Authors:  Edmond M Cronin; Frank M Bogun; Philippe Maury; Petr Peichl; Minglong Chen; Narayanan Namboodiri; Luis Aguinaga; Luiz Roberto Leite; Sana M Al-Khatib; Elad Anter; Antonio Berruezo; David J Callans; Mina K Chung; Phillip Cuculich; Andre d'Avila; Barbara J Deal; Paolo Della Bella; Thomas Deneke; Timm-Michael Dickfeld; Claudio Hadid; Haris M Haqqani; G Neal Kay; Rakesh Latchamsetty; Francis Marchlinski; John M Miller; Akihiko Nogami; Akash R Patel; Rajeev Kumar Pathak; Luis C Sáenz Morales; Pasquale Santangeli; John L Sapp; Andrea Sarkozy; Kyoko Soejima; William G Stevenson; Usha B Tedrow; Wendy S Tzou; Niraj Varma; Katja Zeppenfeld
Journal:  Europace       Date:  2019-08-01       Impact factor: 5.214

Review 7.  Catheter ablation for premature ventricular contractions and ventricular tachycardia in patients with heart failure.

Authors:  Saurabh Kumar; William G Stevenson; Roy M John
Journal:  Curr Cardiol Rep       Date:  2014-09       Impact factor: 2.931

8.  VT ablation: New Developments and Approaches.

Authors:  Zhiyu Ling; Adithya Hari; Harikrishna Tandri
Journal:  Curr Treat Options Cardiovasc Med       Date:  2014-04

9.  Transcoronary mapping and chemical ablation of ventricular tachycardia in no-entry left ventricle.

Authors:  Shohei Kataoka; Ken Kato; Hiroyuki Tanaka; Tamotsu Tejima
Journal:  J Cardiol Cases       Date:  2019-08-22

10.  Biophysical parameters during radiofrequency catheter ablation of scar-mediated ventricular tachycardia: epicardial and endocardial applications via manual and magnetic navigation.

Authors:  Tara Bourke; Eric Buch; Nilesh Mathuria; Yoav Michowitz; Ricky Yu; Ravi Mandapati; Kalyanam Shivkumar; Roderick Tung
Journal:  J Cardiovasc Electrophysiol       Date:  2014-07-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.